American heart journal
Audio Summaries

Recurrent myocardial infarction identified by centralized troponin review: Insights from the MINT trial

Aug 9, 2026

The authors aimed to evaluate the effectiveness of centralized troponin testing in identifying recurrent myocardial infarctions (MIs) in patients with acute MI and anemia from the MINT trial. Their findings revealed that centralized review identified over half of recurrent MI cases, with patients having centrally identified MIs experiencing a significantly higher risk of cardiac death compared to those without recurrent MIs. This suggests that routine troponin testing may enhance the detection of recurrent MIs and inform patient prognosis.

Pregnancy Outcomes in Women with a History of Myocarditis

Aug 7, 2026

This study aims to evaluate maternal and fetal outcomes in pregnant women with a history of myocarditis or perimyocarditis. The findings indicate that the majority of these women do not experience adverse cardiac events during pregnancy, although echocardiographic monitoring is recommended to detect any potential declines in left ventricular function. Notably, there were no maternal or fetal deaths reported, and a small percentage of pregnancies resulted in premature delivery.

HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics

Aug 7, 2026

The ORION-4 trial aims to evaluate the efficacy and safety of inclisiran, a novel siRNA therapy targeting PCSK9, in reducing major adverse cardiovascular events among individuals with pre-existing atherosclerotic cardiovascular disease. With a planned enrollment of approximately 15,000 participants and a follow-up period of at least five years, the study seeks to determine whether inclisiran can significantly lower cardiovascular risks compared to a placebo. Results are expected in early 2027, potentially establishing inclisiran as a scalable treatment option in lipid management.

Efficacy and safety of revascularization in patients with chronic limb-threatening ischemia by kidney function

Aug 5, 2026

The authors aimed to determine how kidney function affects the efficacy and safety of surgical versus endovascular revascularization in patients with chronic limb-threatening ischemia (CLTI). Their analysis of the BEST-CLI trial revealed that while surgical revascularization led to fewer days with major adverse limb events across all kidney function groups, its mortality benefits diminished in patients with advanced chronic kidney disease. These findings suggest the need for personalized revascularization strategies based on kidney function, although further prospective studies are necessary to confirm these results.

Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor-neprilysin inhibition in acute heart failure: insights from the PREMIER study

Aug 1, 2026

The authors aimed to investigate whether estimated total blood volume (TBV) influences the reduction of NT-proBNP levels in acute heart failure patients treated with sacubitril/valsartan (Sac/Val) compared to those receiving ACEI/ARB therapy. Their analysis of data from the PREMIER study found that higher TBV was associated with a greater reduction in NT-proBNP levels after Sac/Val, particularly in patients with left ventricular ejection fraction (LVEF) ≥40%. These results suggest a potential relationship between TBV and biomarker response, warranting further validation.

Reconsidering Fibrinolysis in Selected Patients with Non-ST-Elevation Acute Coronary Syndrome: A Hypothesis-Generating, Research-Based Framework

Jul 31, 2026

The authors explore whether fibrinolytic therapy could be beneficial for selected patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) who are identified as having acute coronary artery occlusion through advanced diagnostic techniques, such as artificial intelligence-enhanced electrocardiography. They propose a research-based framework to investigate the potential risks and benefits of this therapy in situations where timely angiographic evaluation or percutaneous coronary intervention is unavailable. The article aims to generate hypotheses for future studies rather than suggesting immediate changes to clinical practice.

Rationale, Design, and Experiences from the Vanguard Phase of the Bariatric Surgery for the Reduction of Cardiovascular Events (BRAVE) Trial

Jul 25, 2026

The BRAVE trial aims to determine whether metabolic/bariatric surgery (MBS) can effectively reduce major cardiovascular events compared to guideline-based medical weight management in high-risk obese patients. This multi-center, open-label randomized controlled trial has enrolled 200 participants in its vanguard phase, addressing recruitment challenges while focusing on a population with significant comorbidities. The study seeks to fill the evidence gap regarding the cardiovascular benefits of MBS in this demographic.

Intensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients with Type 2 Diabetes: Rationale, Design and Baseline Characteristics of the OPTIMAL-DIABETES Randomized Trial

Jul 24, 2026

The OPTIMAL-DIABETES trial aims to determine whether targeting a systolic blood pressure (SBP) of less than 120 mmHg reduces major cardiovascular events more effectively than a target of less than 140 mmHg in patients with type 2 diabetes and high cardiovascular risk. This multicenter, randomized clinical trial involves a diverse population and will assess outcomes over a maximum follow-up of 48 months. The findings are expected to provide important insights into the optimal blood pressure management strategy for this high-risk group.

Rationale and Design of the TAILOR-HCM Multicenter Randomized Controlled Trial: Transapical Beating-Heart Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy

Jul 22, 2026

The TAILOR-HCM trial aims to evaluate the safety and efficacy of transapical beating-heart septal myectomy (TA-BSM) compared to conventional septal myectomy (CSM) in patients with obstructive hypertrophic cardiomyopathy (oHCM). This multicenter, randomized controlled trial will assess whether TA-BSM can achieve similar clinical outcomes as CSM, particularly in relieving left ventricular outflow tract obstruction, while also examining safety outcomes and quality of life. The findings could potentially expand treatment options for patients with oHCM by providing evidence for a less complex surgical approach.

Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange (SCD-CARRE) trial

Jul 15, 2026

The Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange (SCD-CARRE) trial aims to determine whether an automated chronic red blood cell exchange (RBCX) transfusion strategy can reduce acute health care encounters and mortality while improving quality of life and organ function in adults with sickle cell disease at high risk of death. The study enrolled 173 participants with specific cardiovascular and renal risk factors, comparing outcomes between those receiving RBCX plus standard care and those receiving standard care alone. Results are pending, but the trial emphasizes the importance of patient-centered outcomes and the preservation of cardiovascular health in this population.